知镜 Cognispect · 医学文献与研究工作台

Diabetes mellitus attenuates response to anti-CD20 therapy in primary membranous nephropathy despite equivalent B-cell depletion.

Xu X, Wu M, Zhao F, Li J, Chen Y, Lu R, Zha Y, Zhang Y, Peng H, Cao H, He L.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026-10-01 · PMID 41860432

文献摘要

Background and hypothesis Primary membranous nephropathy (MN) and diabetes mellitus (DM) are common comorbidities, yet the impact of DM on the response to anti-CD20 monoclonal antibody therapy in MN remains unclear. We hypothesized that despite comparable B-cell depletion, MN patients with comorbid DM would exhibit a reduced treatment response compared to nondiabetic MN patients. Methods In this retrospective cohort study, we included adults with primary MN who received at least one complete course of anti-CD20 antibody therapy. Propensity score matching (1:2) was applied based on age, sex, baseline estimated glomerular filtration rate, urinary protein, and PLA2R antibody status. The primary outcome was remission (complete or partial) of proteinuria at 3, 6, 9, and 12 months. Secondary outcomes included immunological remission, B-cell depletion, and changes in renal parameters. Multivariable logistic regression, Kaplan-Meier analysis, and subgroup analyses were used to compare outcomes between MN patients with (MN + DM) and without diabetes (MN). Results After matching, 207 patients were included (72 MN + DM, 135 MN). B-cell depletion and immunological remission rates showed no statistically significant differences between groups over the 12-month follow-up period. However, MN patients had significantly higher overall remission rates at 9 months [94% vs. 77%; odds ratio (OR) = 4.55, 95% confidence interval (CI) = 1.52-12.50, P Conclusion Despite equivalent B-cell depletion, MN with DM patients show a reduced response to anti-CD20 antibody therapy relative to nondiabetic patients, underscoring that tight glycemic control, early supplementary anti-CD20 dosing for poor response, and combined immunosuppressive regimens may enhance their clinical outcomes.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。